CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 111 entries

View as:

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Phase: N/A Priority: Normal

NCT ID: NCT04346108 Org: User:

Start: 08/11/20 End: 12/22/21 Due: 12/22/22

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Phase: N/A Priority: Normal

NCT ID: NCT00189982 Org: User:

Start: 12/17/04 End: 11/10/06 Due: 11/10/07

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

Phase: N/A Priority: Normal

NCT ID: NCT01541670 Org: User:

Start: 11/28/11 End: 12/31/12 Due: 12/31/13

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Phase: N/A Priority: Normal

NCT ID: NCT00818662 Org: User:

Start: 12/19/08 End: 12/10/12 Due: 12/10/13

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Phase: N/A Priority: Normal

NCT ID: NCT02956122 Org: User:

Start: 04/26/17 End: 05/03/18 Due: 05/03/19

A Study of ADVATE in People With Hemophilia A in India

Phase: N/A Priority: Normal

NCT ID: NCT04985682 Org: User:

Start: 01/14/22 End: 02/10/23 Due: 02/10/24

Phase 2/3 Study of IGSC, 20% in PIDD

Phase: N/A Priority: Normal

NCT ID: NCT01218438 Org: User:

Start: 01/28/13 End: 03/13/15 Due: 03/13/16

BAX 855 Pediatric Study

Phase: N/A Priority: Normal

NCT ID: NCT02210091 Org: User:

Start: 10/31/14 End: 10/23/15 Due: 10/23/16

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Phase: N/A Priority: Normal

NCT ID: NCT02932618 Org: User:

Start: 11/06/17 End: 03/31/26 Due: 03/31/27

GAS-Hem Feasibility Study

Phase: N/A Priority: Normal

NCT ID: NCT02674997 Org: User:

Start: 08/05/16 End: 11/02/16 Due: 11/02/17

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Phase: N/A Priority: Normal

NCT ID: NCT03277313 Org: User:

Start: 09/25/17 End: 07/20/22 Due: 07/20/23

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Phase: N/A Priority: Normal

NCT ID: NCT00357656 Org: User:

Start: 05/29/06 End: 12/09/15 Due: 12/09/16

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Phase: N/A Priority: Normal

NCT ID: NCT02593188 Org: User:

Start: 11/12/15 End: 10/21/21 Due: 10/21/22

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Phase: N/A Priority: Normal

NCT ID: NCT00161993 Org: User:

Start: 06/13/02 End: 09/24/03 Due: 09/24/04

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Phase: N/A Priority: Normal

NCT ID: NCT01736475 Org: User:

Start: 01/31/13 End: 07/17/14 Due: 07/17/15

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

Phase: N/A Priority: Normal

NCT ID: NCT00157092 Org: User:

Start: 03/01/04 End: 10/14/04 Due: 10/14/05

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Phase: N/A Priority: Normal

NCT ID: NCT02764489 Org: User:

Start: 02/12/19 End: 12/27/21 Due: 12/27/22

Phase 1/2 Lyme Vaccine Study

Phase: N/A Priority: Normal

NCT ID: NCT01504347 Org: User:

Start: 03/01/11 End: 02/28/14 Due: 02/28/15

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Phase: N/A Priority: Normal

NCT ID: NCT02216084 Org: User:

Start: 09/30/14 End: 02/22/16 Due: 02/22/17

RIXUBIS PMS India (RIXUBIS PMS)

Phase: N/A Priority: Normal

NCT ID: NCT03565237 Org: User:

Start: 12/07/18 End: 08/11/21 Due: 08/11/22

BAX 802 in CHA With Inhibitors

Phase: N/A Priority: Normal

NCT ID: NCT02895945 Org: User:

Start: 12/22/16 End: 01/22/21 Due: 01/22/22

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Phase: N/A Priority: Normal

NCT ID: NCT00162006 Org: User:

Start: 01/13/03 End: 12/03/03 Due: 12/03/04

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Phase: N/A Priority: Normal

NCT ID: NCT01757405 Org: User:

Start: 02/20/13 End: 11/11/14 Due: 11/11/15

Immune Globulin Subcutaenous (Human), 20%

Phase: N/A Priority: Normal

NCT ID: NCT01412385 Org: User:

Start: 06/20/11 End: 05/13/14 Due: 05/13/15

Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Phase: N/A Priority: Normal

NCT ID: NCT00161707 Org: User:

Start: 01/07/03 End: 10/01/03 Due: 10/01/04

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)	NCT04346108	Baxalta now part of Shire	user2@example.com	None	2020-08-11	2021-12-22	2022-12-22	-	-	2025-07-14
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101	NCT00189982	Baxalta now part of Shire	user2@example.com	None	2004-12-17	2006-11-10	2007-11-10	-	-	2025-07-14
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis	NCT01541670	Baxalta now part of Shire	user2@example.com	None	2011-11-28	2012-12-31	2013-12-31	-	-	2025-07-14
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease	NCT00818662	Baxalta now part of Shire	user2@example.com	None	2008-12-19	2012-12-10	2013-12-10	-	-	2025-07-14
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD	NCT02956122	Baxalta now part of Shire	user2@example.com	None	2017-04-26	2018-05-03	2019-05-03	-	-	2025-07-14
A Study of ADVATE in People With Hemophilia A in India	NCT04985682	Baxalta now part of Shire	user2@example.com	None	2022-01-14	2023-02-10	2024-02-10	-	-	2025-07-14
Phase 2/3 Study of IGSC, 20% in PIDD	NCT01218438	Baxalta now part of Shire	user2@example.com	None	2013-01-28	2015-03-13	2016-03-13	-	-	2025-07-14
BAX 855 Pediatric Study	NCT02210091	Baxalta now part of Shire	user2@example.com	None	2014-10-31	2015-10-23	2016-10-23	-	-	2025-07-14
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)	NCT02932618	Baxalta now part of Shire	user2@example.com	None	2017-11-06	2026-03-31	2027-03-31	-	-	2025-07-14
GAS-Hem Feasibility Study	NCT02674997	Baxalta now part of Shire	user2@example.com	None	2016-08-05	2016-11-02	2017-11-02	-	-	2025-07-14
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects	NCT03277313	Baxalta now part of Shire	user2@example.com	None	2017-09-25	2022-07-20	2023-07-20	-	-	2025-07-14
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery	NCT00357656	Baxalta now part of Shire	user2@example.com	None	2006-05-29	2015-12-09	2016-12-09	-	-	2025-07-14
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)	NCT02593188	Baxalta now part of Shire	user2@example.com	None	2015-11-12	2021-10-21	2022-10-21	-	-	2025-07-14
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)	NCT00161993	Baxalta now part of Shire	user2@example.com	None	2002-06-13	2003-09-24	2004-09-24	-	-	2025-07-14
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)	NCT01736475	Baxalta now part of Shire	user2@example.com	None	2013-01-31	2014-07-17	2015-07-17	-	-	2025-07-14
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency	NCT00157092	Baxalta now part of Shire	user2@example.com	None	2004-03-01	2004-10-14	2005-10-14	-	-	2025-07-14
FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)	NCT02764489	Baxalta now part of Shire	user2@example.com	None	2019-02-12	2021-12-27	2022-12-27	-	-	2025-07-14
Phase 1/2 Lyme Vaccine Study	NCT01504347	Baxalta now part of Shire	user2@example.com	None	2011-03-01	2014-02-28	2015-02-28	-	-	2025-07-14
Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)	NCT02216084	Baxalta now part of Shire	user2@example.com	None	2014-09-30	2016-02-22	2017-02-22	-	-	2025-07-14
RIXUBIS PMS India (RIXUBIS PMS)	NCT03565237	Baxalta now part of Shire	user2@example.com	None	2018-12-07	2021-08-11	2022-08-11	-	-	2025-07-14
BAX 802 in CHA With Inhibitors	NCT02895945	Baxalta now part of Shire	user2@example.com	None	2016-12-22	2021-01-22	2022-01-22	-	-	2025-07-14
Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura	NCT00162006	Baxalta now part of Shire	user2@example.com	None	2003-01-13	2003-12-03	2004-12-03	-	-	2025-07-14
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen	NCT01757405	Baxalta now part of Shire	user2@example.com	None	2013-02-20	2014-11-11	2015-11-11	-	-	2025-07-14
Immune Globulin Subcutaenous (Human), 20%	NCT01412385	Baxalta now part of Shire	user2@example.com	None	2011-06-20	2014-05-13	2015-05-13	-	-	2025-07-14
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency	NCT00161707	Baxalta now part of Shire	user2@example.com	None	2003-01-07	2003-10-01	2004-10-01	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance